Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer

In high-risk non-muscle invasive bladder cancer (HR-NMIBC), patient outcome is negatively affected by lack of response to <i>Bacillus-Calmette Guérin</i> (BCG) treatment. Lack of response to cisplatin-based neoadjuvant chemotherapy and cisplatin ineligibility reduces successful treatment...

Full description

Bibliographic Details
Main Authors: Florus C. de Jong, Vera C. Rutten, Tahlita C. M. Zuiverloon, Dan Theodorescu
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
bladder cancer
BCG-unresponsive
neoadjuvant chemotherapy
immune checkpoint inhibition
PD-1
PD-L1
Online Access:https://www.mdpi.com/1422-0067/22/6/2800

Internet

https://www.mdpi.com/1422-0067/22/6/2800

Similar Items